XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. Unlike previous generations of antibody therapies, XBiotech’s True Human™ antibodies are 100 percent human, derived from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human™ antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability. XBiotech is currently advancing a robust pipeline of antibody therapies to exceed the standards of care in oncology, inflammatory conditions and infectious diseases. The Company's broad pipeline of True Human™ antibodies are able to potentially deliver unmatched safety and efficacy because they are cloned directly from individual donors who possess natural immunity against certain targeted diseases. As such, True Human™ antibodies retain their natural physiology and tolerance profile, having passed the rigors of immune selection in the body.
Looking for a particular XBiotech USA, Inc. employee's phone or email?
The XBiotech USA, Inc. annual revenue was $19.4 million in 2026.
Queena Han is the Vice President, Finance and Human Resources and Secretary (Principal Financial Officer) of XBiotech USA, Inc..
84 people are employed at XBiotech USA, Inc..
XBiotech USA, Inc. is based in Austin, Texas.
The NAICS codes for XBiotech USA, Inc. are [325, 54, 32, 32541, 541, 3254].
The SIC codes for XBiotech USA, Inc. are [873, 87, 28, 283].